Hansa Biopharma AB banner

Hansa Biopharma AB
OTC:HNSBF

Watchlist Manager
Hansa Biopharma AB Logo
Hansa Biopharma AB
OTC:HNSBF
Watchlist
Price: 2.9 USD Market Closed
Market Cap: $316.6m

Wall Street
Price Targets

HNSBF Price Targets Summary
Hansa Biopharma AB

Wall Street analysts forecast HNSBF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HNSBF is 7.03 USD with a low forecast of 3.2 USD and a high forecast of 9.78 USD.

Lowest
Price Target
3.2 USD
10% Upside
Average
Price Target
7.03 USD
142% Upside
Highest
Price Target
9.78 USD
237% Upside
Hansa Biopharma AB Competitors:
Price Targets
LAND
Gladstone Land Corp
-13% Downside
CIGI
Colliers International Group Inc
11% Upside

Revenue
Forecast

44% / Year
Past Growth
75% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
44% / Year
Past Growth
75% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

For the last 14 years the compound annual growth rate for Hansa Biopharma AB's revenue is 44%. The projected CAGR for the next 3 years is 75%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-59%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-59%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HNSBF's stock price target?
Price Target
7.03 USD

According to Wall Street analysts, the average 1-year price target for HNSBF is 7.03 USD with a low forecast of 3.2 USD and a high forecast of 9.78 USD.

What is Hansa Biopharma AB's Revenue forecast?
Projected CAGR
75%

For the last 14 years the compound annual growth rate for Hansa Biopharma AB's revenue is 44%. The projected CAGR for the next 3 years is 75%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett